These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 29369408)
1. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease. Nagarajan N; Chellam J; Kannan RR J Cell Biochem; 2018 Jun; 119(6):4878-4889. PubMed ID: 29369408 [TBL] [Abstract][Full Text] [Related]
7. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease. Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532 [TBL] [Abstract][Full Text] [Related]
8. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Tomiyama H; Li Y; Funayama M; Hasegawa K; Yoshino H; Kubo S; Sato K; Hattori T; Lu CS; Inzelberg R; Djaldetti R; Melamed E; Amouri R; Gouider-Khouja N; Hentati F; Hatano Y; Wang M; Imamichi Y; Mizoguchi K; Miyajima H; Obata F; Toda T; Farrer MJ; Mizuno Y; Hattori N Mov Disord; 2006 Aug; 21(8):1102-8. PubMed ID: 16622854 [TBL] [Abstract][Full Text] [Related]
9. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419 [TBL] [Abstract][Full Text] [Related]
10. Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2. Park H; Kim T; Kim K; Jang A; Hong S Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361616 [TBL] [Abstract][Full Text] [Related]
11. [Clinical features of LRRK2-associated Parkinson's disease]. Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811 [TBL] [Abstract][Full Text] [Related]
12. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy. Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038 [TBL] [Abstract][Full Text] [Related]
17. G2385R and I2020T Mutations Increase LRRK2 GTPase Activity. Ho DH; Jang J; Joe EH; Son I; Seo H; Seol W Biomed Res Int; 2016; 2016():7917128. PubMed ID: 27314038 [TBL] [Abstract][Full Text] [Related]
18. The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain. Schmidt SH; Knape MJ; Boassa D; Mumdey N; Kornev AP; Ellisman MH; Taylor SS; Herberg FW Proc Natl Acad Sci U S A; 2019 Jul; 116(30):14979-14988. PubMed ID: 31292254 [TBL] [Abstract][Full Text] [Related]
19. Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain. Tan S; Gong X; Liu H; Yao X ACS Chem Neurosci; 2021 Sep; 12(17):3214-3224. PubMed ID: 34387082 [TBL] [Abstract][Full Text] [Related]
20. Identification of LRRK2 Inhibitors through Computational Drug Repurposing. Tan S; Lu R; Yao D; Wang J; Gao P; Xie G; Liu H; Yao X ACS Chem Neurosci; 2023 Feb; 14(3):481-493. PubMed ID: 36649061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]